MD3601283T2 - Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată - Google Patents

Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată

Info

Publication number
MD3601283T2
MD3601283T2 MDE20200142T MDE20200142T MD3601283T2 MD 3601283 T2 MD3601283 T2 MD 3601283T2 MD E20200142 T MDE20200142 T MD E20200142T MD E20200142 T MDE20200142 T MD E20200142T MD 3601283 T2 MD3601283 T2 MD 3601283T2
Authority
MD
Moldova
Prior art keywords
compound
jak inhibitor
inhibitor compound
piperidine
fused imidazo
Prior art date
Application number
MDE20200142T
Other languages
English (en)
Inventor
Paul R Fatheree
Lan Jiang
Robert Murray Mckinnell
Venkat R Thalladi
Hao Zhang
Marta Dabros
Jerry Nzerem
Noah Benjamin
Melanie A Kleinschek
Glenn D Crater
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MD3601283T2 publication Critical patent/MD3601283T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Invenţia furnizeză un compus cu formula 1:1sau o sare farmaceutic acceptabilă a acesteia, care este folositoare ca inhibitor al JAK. Invenţia furnizează de asemenea forme cristaline ale compusului, compoziţii farmaceutice cuprinzând compusul, metode de utilizare a compusului pentru tratarea bolilor susceptibile la un inhibitor al JAK, şi procedee şi intermediary pentru prepararea compusului.
MDE20200142T 2017-05-01 2018-04-30 Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată MD3601283T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492574P 2017-05-01 2017-05-01
PCT/US2018/030148 WO2018204238A1 (en) 2017-05-01 2018-04-30 Fused imidazo-piperidine jak inhibitor compound

Publications (1)

Publication Number Publication Date
MD3601283T2 true MD3601283T2 (ro) 2022-05-31

Family

ID=62165730

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200142T MD3601283T2 (ro) 2017-05-01 2018-04-30 Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată

Country Status (30)

Country Link
US (3) US10493077B2 (ro)
EP (1) EP3601283B1 (ro)
JP (1) JP7098656B2 (ro)
KR (1) KR102550225B1 (ro)
CN (1) CN110573508B (ro)
AR (1) AR111495A1 (ro)
AU (1) AU2018261593B2 (ro)
BR (1) BR112019022648A2 (ro)
CA (1) CA3056283A1 (ro)
CL (1) CL2019003086A1 (ro)
CO (1) CO2019011809A2 (ro)
DK (1) DK3601283T3 (ro)
EA (1) EA201992601A1 (ro)
ES (1) ES2908756T3 (ro)
HR (1) HRP20220330T1 (ro)
IL (1) IL270231B2 (ro)
LT (1) LT3601283T (ro)
MA (1) MA47970B1 (ro)
MD (1) MD3601283T2 (ro)
MX (1) MX2019012942A (ro)
NZ (1) NZ757570A (ro)
PH (1) PH12019502264A1 (ro)
PL (1) PL3601283T3 (ro)
PT (1) PT3601283T (ro)
RS (1) RS62995B1 (ro)
SG (1) SG11201908604YA (ro)
SI (1) SI3601283T1 (ro)
TW (1) TWI760486B (ro)
UA (1) UA124478C2 (ro)
WO (1) WO2018204238A1 (ro)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
AR111241A1 (es) 2017-03-09 2019-06-19 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR102568333B1 (ko) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물을 사용하는 치료 방법
AU2019335199A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
MA53229A (fr) 2018-09-04 2022-05-11 Theravance Biopharma R&D Ip Llc Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
WO2020092019A1 (en) 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as jak inhibitor
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS
PE20212069A1 (es) * 2019-02-25 2021-10-26 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115244047A (zh) * 2020-03-18 2022-10-25 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
US20240092758A1 (en) * 2021-06-25 2024-03-21 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
PT3001903T (pt) 2009-12-21 2017-12-18 Samumed Llc 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
MY187446A (en) 2013-12-05 2021-09-22 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AP2016009562A0 (en) 2014-05-14 2016-11-30 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
AR111241A1 (es) 2017-03-09 2019-06-19 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR102568333B1 (ko) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물을 사용하는 치료 방법
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형

Also Published As

Publication number Publication date
PT3601283T (pt) 2022-02-10
CL2019003086A1 (es) 2020-01-24
SG11201908604YA (en) 2019-10-30
MA47970B1 (fr) 2022-03-31
EP3601283B1 (en) 2021-12-29
DK3601283T3 (da) 2022-04-04
CN110573508A (zh) 2019-12-13
US10493077B2 (en) 2019-12-03
PL3601283T3 (pl) 2022-05-02
TWI760486B (zh) 2022-04-11
TW201841914A (zh) 2018-12-01
LT3601283T (lt) 2022-02-25
KR102550225B1 (ko) 2023-07-03
IL270231B2 (en) 2023-08-01
MX2019012942A (es) 2019-12-16
CO2019011809A2 (es) 2020-01-17
EP3601283A1 (en) 2020-02-05
HRP20220330T1 (hr) 2022-05-13
US20200046719A1 (en) 2020-02-13
US20220008428A1 (en) 2022-01-13
AU2018261593B2 (en) 2021-08-26
SI3601283T1 (sl) 2022-04-29
US11160810B2 (en) 2021-11-02
EA201992601A1 (ru) 2020-03-03
CN110573508B (zh) 2022-07-05
JP2020518581A (ja) 2020-06-25
AR111495A1 (es) 2019-07-17
BR112019022648A2 (pt) 2020-05-19
ES2908756T3 (es) 2022-05-03
KR20190142389A (ko) 2019-12-26
IL270231B1 (en) 2023-04-01
AU2018261593A1 (en) 2019-10-17
IL270231A (ro) 2019-12-31
WO2018204238A1 (en) 2018-11-08
PH12019502264A1 (en) 2020-09-21
NZ757570A (en) 2021-07-30
US20180311255A1 (en) 2018-11-01
UA124478C2 (uk) 2021-09-22
CA3056283A1 (en) 2018-11-08
JP7098656B2 (ja) 2022-07-11
RS62995B1 (sr) 2022-03-31

Similar Documents

Publication Publication Date Title
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
MD3672965T2 (ro) Compusi ai pirimidinei ca inhibitori ai kinazei JAK
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
NZ764150A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
EA202190452A1 (ru) Ингибиторы cdk8/19
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.